FrancophonIA/ELRC3.0 huggingface dataset:
English: Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe EU/1/07/412/023
Lithuanian: Abseamed 30 000 TV/0,75 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/023
English: Baseline Characteristics for Subjects with sEPO < 200 mU/mL at Screening
Lithuanian: Pradinės tiriamųjų, kurių sEPO atrankos metu buvo < 200 mV/ml, charakteristikos
English: Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL
Lithuanian: Abseamed 30 000 TV/0,75 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 40 000 TV epoetino alfa*, tai atitinka 336,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Each syringe contains 0.6 mL of solution for injection.
Lithuanian: Abseamed 6 000 TV/0,6 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 0,6 ml tirpalo.
English: A pre-filled syringe of 1 mL contains 10,000 international units (IU) corresponding to 84.0 micrograms epoetin alfa.
Lithuanian: Viename 1 ml užpildytame švirkšte yra 10 000 tarptautinių vienetų (TV) epoetino alfa, tai atitinka 84,0 mikrogramus epoetino alfa.
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/009
Lithuanian: Abseamed 5 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/009
English: In paediatric patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable.
Lithuanian: Pacientams vaikams, kuriems yra lėtinis inkstų nepakankamumas ir kuriems nuolat galima venos prieiga (pacientai, kuriems atliekama kraujo dializė), Abseamed rekomenduojama vartoti į veną.
English: INFORMATION IN BRAILLE Abseamed 1,000 IU/0.5 mL
Lithuanian: Abseamed 1 000 TV/0,5 ml
English: Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe EU/1/07/412/019
Lithuanian: Abseamed 9 000 TV/0,9 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/019
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL
Lithuanian: Abseamed 2 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 2 000 TV epoetino alfa*, tai atitinka 16,8 mikrogramus epoetino alfa viename ml.
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL
Lithuanian: Abseamed 1 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 2 000 TV epoetino alfa*, tai atitinka 16,8 mikrogramus epoetino alfa viename ml.
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Each syringe contains 0.3 mL of solution for injection.
Lithuanian: Abseamed 3 000 TV/0,3 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 0,3 ml tirpalo.
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 5 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL
Lithuanian: Abseamed 20 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 40 000 TV epoetino alfa*, tai atitinka 336,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Lithuanian: Abseamed 5 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 0,5 ml tirpalo.
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Lithuanian: Abseamed 20 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 0,5 ml tirpalo.
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/021
Lithuanian: Abseamed 20 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/021
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe EU/1/07/412/011
Lithuanian: Abseamed 6 000 TV/0,6 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/011
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL
Lithuanian: Abseamed 40 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 40 000 TV epoetino alfa*, tai atitinka 336,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/025
Lithuanian: Abseamed 40 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/025
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Lithuanian: Abseamed 40 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 1 ml tirpalo.
English: Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe EU/1/07/412/007
Lithuanian: Abseamed 4 000 TV/0,4 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/007
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe EU/1/07/412/005
Lithuanian: Abseamed 3 000 TV/0,3 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/005
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe EU/1/07/412/017
Lithuanian: Abseamed 7 000 TV/0,7 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/017
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/003
Lithuanian: Abseamed 2 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/003
English: Treatment of symptomatic anaemia in adult chronic renal failure patients
Lithuanian: Simptominės anemijos gydymas pacientams, kuriems yra lėtinis inkstų nepakankamumas
English: At the time of clinical data cutoff, the median progression free survival (PFS) per investigator assessment of disease progression was 7.4 months in each arm (HR 1.09, 95% CI: 0.99, 1.20), indicating the study objective was not met.
Lithuanian: išgyvenamumo neprogresuojant ligai (INL) mediana kiekvienoje grupėje buvo 7,4 mėnesio (RS 1,09;
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Lithuanian: Abseamed 2 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 1 ml tirpalo.
English: Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 8 000 TV/0,8 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 6 000 TV/0,6 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/001
Lithuanian: Abseamed 1 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/001
English: Your doctor will decide how Abseamed will be injected.
Lithuanian: Kaip leisti Abseamed, nuspręs Jūsų gydytojas.
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 7 000 TV/0,7 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 8 000 TV/0,8 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/015
Lithuanian: Abseamed 10 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte EU/1/07/412/015
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Lithuanian: Abseamed 1 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 0,5 ml tirpalo.
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Lithuanian: Abseamed 10 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte Kiekviename užpildytame švirkšte yra 1 ml tirpalo.
English: Abseamed is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.
Lithuanian: Abseamed skirtas suaugusiesiems, kuriems taikoma chemoterapija dėl solidinių navikų, piktybinės limfomos ar daugybinės mielomos, bei kuriems, įvertinus bendrą paciento būklę (pvz.
English: Abseamed should be administered by the intravenous route.
Lithuanian: Abseamed turi būti vartojamas į veną.
English: Abseamed should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)).
Lithuanian: Abseamed skirtas gydyti simptominei anemijai (hemoglobino koncentracija ≤ 10 g/dl)
English: Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 9 000 TV/0,9 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 9 000 TV/0,9 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 4 000 TV/0,4 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 6 000 TV/0,6 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 4 000 TV/0,4 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 5 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 3 000 TV/0,3 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 7 000 TV/0,7 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 3 000 TV/0,3 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Lithuanian: Abseamed 10 000 TV/1 ml injekcinis tirpalas užpildytame švirkšte Viename tirpalo ml yra 10 000 TV epoetino alfa*, tai atitinka 84,0 mikrogramus epoetino alfa viename ml.
English: Abseamed is provided with or without a needle safety guard and you will be shown how to use this by your doctor or nurse.
Lithuanian: Kaip vaisto leistis, Jums parodys gydytojas arba slaugytojas.
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 2 000 TV/1 ml injekcija Epoetinas alfa i.v.
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 20 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Abseamed, treatment with Abseamed must not be restarted in this patient at any time.
Lithuanian: Jei pacientui vartojant Abseamed pasireiškė sunki nepageidaujama odos reakcija, pvz.
English: Caution should be exercised with escalation of Abseamed doses in patients with chronic renal failure.
Lithuanian: Pacientams, kuriems yra lėtinis inkstų nepakankamumas, Abseamed dozes reikia didinti atsargiai.
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 1 000 TV/0,5 ml injekcinis tirpalas užpildytame švirkšte Epoetinas alfa
English: Abseamed should be administered as a subcutaneous injection.
Lithuanian: Abseamed reikia vartoti po oda.
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 40 000 TV/1 ml injekcija Epoetinas alfa i.v.
English: Instructions on how to inject Abseamed yourself
Lithuanian: Nurodymai kaip patiems susišvirkšti Abseamed
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Lithuanian: Abseamed 10 000 TV/1 ml injekcija Epoetinas alfa i.v.
English: 1081 CN Amsterdam The Netherlands
Lithuanian: 1081 CN Amsterdam Nyderlandai
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/ema/.
Lithuanian: Išsami informacija apie šį vaistą pateikiama Europos vaistų agentūros tinklalapyje http://www.ema.europa.eu/ema/.
English: This medicinal product should not be used any further.
Lithuanian: Šio vaistinio preparato nebegalima toliau vartoti.
English: Store and transport refrigerated (2°C - 8°C).
Lithuanian: Laikyti ir transportuoti šaltai (2 °C -8 °C).
English: The patients were between 22 months and 72 years old.
Lithuanian: Pacientų amžius svyravo nuo 22 mėnesių iki 72 metų.
English: The duration of the treatment is determined by the doctor and may vary for each patient.
Lithuanian: Gydymo trukmę nustato gydytojas ir kiekvieno paciento atveju ji gali būti skirtinga.
English: Two of these 8 fatalities occurred within the first 3 years of treatment and 6 of them occurred 8-13 years after treatment.
Lithuanian: Du iš šių 8 pacientų mirė per pirmus 3 gydymo metus, kiti 6 mirė praėjus 8-13 metų po gydymo.
English: Carmustine Obvius may cause the following side effects:
Lithuanian: Carmustine Obvius gali sukelti toliau nurodytus šalutinio poveikio reiškinius:
English: What Carmustine Obvius is and what it is used for
Lithuanian: Kas yra Carmustine Obvius ir kam jis vartojamas
English: Obvius Investment B.V. De Cuserstraat 93
Lithuanian: V. De Cuserstraat 93
English: Doses will be adjusted according to how you respond to the treatment.
Lithuanian: Dozės bus koreguojamos pagal jūsų atsaką į gydymą.
English: Initial doses
Lithuanian: Pirminės dozės
English: Carmustine Obvius should not be used during pregnancy because it may harm your unborn baby.
Lithuanian: Carmustine Obvius negalima vartoti nėštumo metu, nes jis gali pakenkti dar negimusiam kūdikiui.
English: Nadir after prior dose
Lithuanian: Nadyras po ankstesnės dozės
English: For dissolving purposes only
Lithuanian: Naudoti tik ištirpinimo tikslais
English: Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed may not reflect the rates observed in clinical practice.
Lithuanian: Kadangi klinikiniai tyrimai atliekami labai specifinėmis sąlygomis, nustatyti nepageidaujamų reakcijų rodikliai gali neatitikti klinikinėje praktikoje nustatomų rodiklių.
English: The half-life α is 1-4 minutes and the half-life β is 18-69 minutes.
Lithuanian: α pusėjimo trukmė yra 1-4 minutės, β pusėjimo trukmė - 1869 minutės.
English: Percentage of prior dose to be given
Lithuanian: Ankstesnės dozės procentinė dalis, kurią reikėtų suleisti
English: The kinetic of carmustine in humans is characterised by a two-chamber model.
Lithuanian: Karmustino kinetiką žmogaus organizme apibūdina dviejų kamerų modelis.
English: Pulmonary toxicity has been observed in up to 30% of patients.
Lithuanian: Toksinis poveikis plaučiams nustatytas iki 30 proc. pacientų.
English: Lung damage may occur years after treatment.
Lithuanian: Plaučių audinio pažeidimai gali išsivystyti praėjus keleriems metams po gydymo.
English: All patients younger than 5 years of age at the time of treatment died from pulmonary fibrosis; neither the carmustine dose nor an additional vincristine dose or spinal radiation had any influence on the fatal outcome.
Lithuanian: Visi pacientai, kurie gydymo laikotarpiu buvo jaunesni nei 5 metų, mirė nuo plaučių fibrozės; nei karmustino dozė, nei papildoma vinkristino dozė ar stuburo spindulinis gydymas neturėjo įtakos mirtinoms gydymo pasekmėms.
English: Carmustine Obvius with alcohol
Lithuanian: Carmustine Obvius ir alkoholis
English: Carmustine Obvius should not be used in children and adolescents due to high risk of pulmonary toxicity.
Lithuanian: Carmustine Obvius negalima vartoti vaikams ir paaugliams dėl didelės toksinio poveikio plaučiams rizikos.
English: Carmustine Obvius is a medicine which contains carmustine.
Lithuanian: Carmustine Obvius - tai vaistas, kurio sudėtyje yra karmustino.
English: Other medicines and Carmustine Obvius
Lithuanian: Kiti vaistai ir Carmustine Obvius
English: In case the tumor remains incurable or some serious or intolerable adverse reactions appear, the carmustine therapy must be terminated.
Lithuanian: Jeigu navikas išlieka neišgydomas arba pasireiškia tam tikros sunkios ar netoleruojamos nepageidaujamos reakcijos, karmustino terapiją būtina nutraukti.
English: The following table includes adverse reactions of carmustine listed by MedDRA system organ class and frequency convention presented in order of decreasing seriousness: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to < 1/1,000); very rare (<1/10,000), not known (frequency cannot be estimated from the available data).
Lithuanian: Toliau pateiktoje lentelėje nepageidaujamos reakcijos nurodytos pagal sisteminę organų klasę ir dažnį, nuo sunkiausios iki lengviausios: labai dažnos (≥1/10); dažnos (nuo ≥1/100 iki <1/10); nedažnos (nuo ≥1/1 000 iki <1/100); retos (nuo ≥1/10 000 iki <1/1 000); labai retos (<1/10 000), dažnis nežinomas (negali būti įvertintas pagal turimus duomenis).
English: Ethanol.
Lithuanian: etanolis.
English: The median age of patients who died on treatment was 2.5 years (1-12 years), the median age of long-term survivors on treatment was 10 years (5-16 years).
Lithuanian: Pacientų, kurie mirė vartodami vaistinį preparatą, amžiaus mediana siekė 2,5 metų (1-12 metų), o pacientų, kurie vartodami vaistinį preparatą išgyveno ilgą laiką, amžiaus mediana siekė 10 metų (516 metų).
English: Carmustine should not be administered to patients who are pregnant.
Lithuanian: Karmustinas neturėtų būti skiriamas nėščioms pacientėms.
English: Monitoring and subsequent doses
Lithuanian: Stebėjimas ir tolesnės dozės
English: Approximately 60-70% of a total dose is excreted in the urine in 96 hours and about 10% as respiratory CO2.
Lithuanian: visos dozės pašalinama iš organizmo su šlapimu per 96 valandas, maždaug 10 proc. iškvepiama kaip CO2.
English: Leucocytes/mm3
Lithuanian: Leukocitai/mm3
English: - The active substance is carmustine.
Lithuanian: - Veiklioji medžiaga yra karmustinas.
English: The amount of alcohol in this medicine may alter the effects of other medicines.
Lithuanian: Šiame vaiste esantis alkoholio kiekis gali turėti įtakos kitų vaistų poveikiui.
English: Emetogenic potential.
Lithuanian: Emetogeninis potencialas
English: Such products are not accepted for use due to the risk of temperature excursions to more than 30°C.
Lithuanian: Tokie vaistiniai preparatai netinkami vartoti dėl galimų temperatūros nukrypimų iki daugiau nei 30 °C.
English: There are no limits for the period of application of carmustine therapy.
Lithuanian: Karmustino terapijos taikymo laikotarpis neapribotas.
English: The following schedule is suggested as a guide to dosage adjustment:
Lithuanian: Toliau pateiktas planas siūlomas kaip rekomendacija dėl dozių koregavimo.
English: This corresponds to 11.2 ml of beer or 4.65 ml wine, per dose.
Lithuanian: Tai atitinka 11,2 ml alaus arba 4,65 ml vyno vienoje dozėje.
English: The table includes adverse reactions that were presented during treatment with this medicinal product but may not necessarily have a causal relationship with the medicinal product.
Lithuanian: Lentelėje nurodytos nepageidaujamos reakcijos, kurios pasireiškė gydymo šiuo vaistiniu preparatu laikotarpiu, bet nebūtinai yra priežastiniu ryšiu susijusios su šiuo vaistiniu preparatu.
English: Children and adolescents
Lithuanian: - vaikams ir paaugliams;
English: Long-term follow-up observation of 17 patients who survived brain tumours in childhood showed that 8 of them succumbed to pulmonary fibrosis.
Lithuanian: Ilgalaikio 17-os pacientų, kurie išgyveno po vaikystėje diagnozuoto galvos smegenų naviko, tolesnio stebėjimo duomenimis, aštuoni iš šių pacientų mirė nuo plaučių fibrozės.
English: Because of the good lipid solubility and the lack of ionisation at the physiological pH, carmustine is very well transferred through the blood-brain barrier.
Lithuanian: Dėl gero tirpumo riebaluose ir nevykstančios jonizacijos esant fiziologiniam pH, karmustinas labai lengvai pereina kraujo-galvos smegenų barjerą.
English: The fate of the remainder is undetermined.
Lithuanian: Kas nutinka likusiai medžiagos daliai, nenustatyta.
English: Pulmonary fibrosis (with fatal outcome), pulmonary infiltration
Lithuanian: Plaučių fibrozė (su mirtinais padariniais), plaučių infiltracija
English: Tell your doctor or nurse immediately if you notice any of the following:
Lithuanian: Nedelsdami kreipkitės į gydytoją arba slaugytoją, jeigu jums pasireiškė bent vienas iš toliau nurodytų reiškinių:
English: During treatment, lung function tests (FVC, DLCO) should be performed regularly.
Lithuanian: Gydymo laikotarpiu turėtų būti reguliariai atliekami plaučių veiklos tyrimai (FVC, DLCO).
English: To be taken into account in pregnant or breast-feeding women, children and highrisk groups such as patients with liver disease, or epilepsy.
Lithuanian: Į tai reikia atsižvelgti gydant nėščias ar žindančias moteris, vaikus ir prie didelės rizikos grupių priskiriamus pacientus, pvz., sergančius kepenų liga arba epilepsija.
English: In patients having received carmustine in childhood or adolescence, cases of extremely delayedonset pulmonary fibrosis (up to 17 years after treatment) have been described.
Lithuanian: Pacientų, kurie karmustinu buvo gydomi vaikystėje arba paauglystėje, populiacijoje aprašyti itin uždelstos plaučių fibrozės atvejai (išsivystė praėjus iki 17 metų po gydymo).